Browsing by Author "Santos, Rita Natália Couto dos"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Systematic review of clinical trials on the potential of probiotics for the treatment of COVID‑19Publication . Santos, Rita Natália Couto dos; Moreira, Fernando Xavier Ferreira; Cruz, Agostinho Luís Silva; Cruz, Agostinho; Moreira, FernandoIn recent decades, new deadly coronaviruses causing highly infectious diseases have emerged in human society, resulting in threats to public health and the global economy. In December 2019, in the province of Wuhan, China, the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) emerged. This infection was classified as the coronavirus dis‑ ease 2019 (COVID‑19) pandemic. Probiotics are live microorganisms whose administra‑ tion in adequate quantities has been associated with health benefits for the host, contribut‑ ing to the treatment and prevention of multiple pathologies. The present study aims to review scientific evidence on the impact of probiotic treatment on the progression of mor‑ bidity due to SARS‑CoV‑2. The research was conducted in the Cochrane Library, Clinical Trials, EBSCO, Medline, Web of Science, and Science Direct databases. Inclusion criteria were as follows: study period between 2019 and 2023; language in English or Portuguese; methodology based on clinical trials; studies in humans with a confirmed diagnosis of SARS‑CoV‑2 and administration of probiotics in the treatment of the pathology. Five stud‑ ies were included in this review, recruiting a total of patients ranging from 23 to 300 in‑ dividuals. The main positive results of the probiotic intervention compared to the control group were nearly an improvement in digestive symptoms (65% vs. 88%, p‑value 0.06) and overall symptoms (88.6% vs. 70.8%; p‑value 0.03). Also, in the probiotic group, there was an increase in serum concentrations of immunoglobulin G (IgG) in the receptor‑binding domain/spike 1 (RBD/S1) (225.9 vs. 105.6 binding antibody units/mL, p‑value 0.05). The major limitation is related to the fact that in all five studies, patients were concomitantly treated with several other drugs whose action may have influenced the observed results. The conducted studies suggest that the use of probiotics enhances a decrease in morbidity in SARS‑CoV‑2, although more studies are needed to confirm their efficacy in the disease.
- Uso de probióticos na evolução da morbilidade na SARS-CoV-2: revisão sistemáticaPublication . Santos, Rita Natália Couto dos; Moreira, Fernando Xavier Ferreira; Cruz, Agostinho Luís SilvaEm dezembro de 2019, na província de Wuhan, surgiu o coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2). Esta infeção foi classificada como pandemia da doença coronavírus 2019. Os probióticos são microrganismos vivos, cuja administração em quantidades adequadas, tem sido associada a benefícios para a saúde do hospedeiro. Este estudo tem como objetivo verificar o efeito do uso dos probióticos na evolução na morbilidade na SARS-CoV-2. Foi realizada uma revisão sistemática, tendo a pesquisa sido realizada nas bases de dados Cochrane Library, Clinical Trials, EBSCO, Medline, Web of Science e Science Direct. Consideraram-se como critérios de inclusão: período de estudo entre 2019 e 2023; idioma em Inglês ou Português; estudos em ensaios clínicos; estudos em humanos com diagnóstico confirmado de SARS-CoV-2 e administração de probióticos na SARS-CoV-2. Foram incluídos 5 estudos nesta revisão, cujo tamanho da amostra variou entre 23 e 300 doentes, com um período de estudo reduzido. Os principais resultados sugerem a melhoria sintomatológica, um aumento na resposta imunitária humoral aos antigénios virais e uma redução nos marcadores inflamatórios. Todavia, estes resultados necessitam de mais estudos para comprovar a eficácia dos probióticos, sobretudo no que concerne à evolução da morbilidade da SARS-CoV-2.